Thursday 16 October, 2025
Introduction: Myelodysplastic syndromes (MDS) represent a group of bone marrow disorders involving cytopenia (anemia, neutropenia, thrombocytopenia), hypercellular bone marrow, and…
Read morePoster: Drug/Disease Modelling - Oncology
Translational PK-Tumor Growth Inhibition (TGI) modeling of type 1 PRMT and PRMT5 inhibitor combination to predict clinical response
Thursday 16 October, 2025
Objectives: GSK3368715 and GSK3326595 are novel type 1 PRotein MethylTransferase (PRMT) and PRMT5 inhibitors respectively which have been investigated as…
Read moreA time-to-event analysis of paclitaxel-related peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first line chemotherapy
Thursday 16 October, 2025
Objectives: Peripheral neuropathy (PN), a dose-limiting adverse event of paclitaxel (PTX) affects > 20% of patients on PTX therapy and…
Read moreExamining the relationship between paclitaxel exposure and peripheral neuropathy in non-small cell lung cancer
Thursday 16 October, 2025
Objectives: Peripheral neuropathy (PN) is a dose-limiting, cumulative adverse event of paclitaxel (PTX) reported by more than 20% of patients on…
Read moreTime-to-event analysis framework to evaluate the impact of paclitaxel exposure on peripheral neuropathy in patients with advanced non-small cell lung cancer receiving first-line chemotherapy
Thursday 16 October, 2025
Objectives: Peripheral neuropathy (PN), a dose-limiting paclitaxel-related toxicity, affects >20% of patients on paclitaxel (PTX) therapy and negatively impacts quality…
Read moreRadiation and anti-PD-L1 treatment combinations: Immune cell responses and dose scheduling optimization using a joint experimental and systems modeling approach
Thursday 16 October, 2025
Objectives: Investigations into the interactions between radiotherapy(RT) and the host immune system have uncovered new mechanisms that can potentially be…
Read morePopulation Pharmacokinetic Modeling of Brentuximab Vedotin, a CD30-Directed Antibody-Drug Conjugate, and its cytotoxic payload (MMAE) in Patients With Various Hematological Malignancies
Thursday 16 October, 2025
Objectives: To develop population pharmacokinetic models of Brentuximab Vedotin (BV), an antibody-drug conjugate (ADC) and its cytotoxic payload (MMAE) following…
Read morePredictive Systems Medicine Modelling of Myelosuppression and Recovery of Hematopoietic Cells among Adult Patients with Hematopoietic Cell Transplantation
Thursday 16 October, 2025
Introduction: Allogeneic Hematopoietic Cell Transplantation (HCT) can cure or improve the outcome in a variety of hematological diseases. Currently, predictive…
Read moreA model-based approach to evaluate the effect of isatuximab in combination with pomalidomide and dexamethasone using multiple composite endpoints: Application to the ICARIA study in relapsed/refractory multiple myeloma
Thursday 16 October, 2025
Objectives: Isatuximab (Isa) is an IgG1 monoclonal antibody that binds a specific epitope on the CD38 transmembrane glycoprotein. Isa has…
Read moreFrequency-domain derived optimisation of cell cycle specific cancer treatment
Thursday 16 October, 2025
Objectives: It was recently demonstrated that key biological control systems (such as the MAPK pathway) are highly sensitive to the…
Read more